Parallax Volatility Advisers
CLDX icon

Parallax Volatility Advisers’s Celldex Therapeutics CLDX Stock Holding History

Parallax Volatility Advisers’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-22,333
Closed -$5.25M – 2588
2015
Q4 		$5.25M Buy
+22,333
New +$4.87M 0.01% 663

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Parallax Volatility Advisers's CLDX Position: Q2 2023 in Review

Parallax Volatility Advisers sold out of Celldex Therapeutics (CLDX) in Q2 2023, closing a stake of 8,265 shares — an estimated $297K sold.

Parallax Volatility Advisers first reported a position in CLDX in Q4 2015 and held it in 4 quarters. The position peaked at $3.18M in Q4 2015. 150 funds tracked by Wall St. Rank hold CLDX as of Q2 2023.

  • Parallax Volatility Advisers reported no remaining Celldex Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Parallax Volatility Advisers sold 8,265 Celldex Therapeutics shares in Q2 2023, an estimated $297K.
  • Parallax Volatility Advisers first reported a position in Celldex Therapeutics in Q4 2015 and held it in 4 quarters.
  • Parallax Volatility Advisers's Celldex Therapeutics position peaked at $3.18M in Q4 2015.
  • 150 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2023.

Based on Parallax Volatility Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.